Patents Examined by Sharon Turner
-
Patent number: 7214656Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 19, 2001Date of Patent: May 8, 2007Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7193045Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: December 26, 2001Date of Patent: March 20, 2007Assignee: Genetech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Colin K. Watanabe, William I. Wood
-
Patent number: 7193074Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 8, 2002Date of Patent: March 20, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
-
Patent number: RE46912Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.Type: GrantFiled: November 10, 2014Date of Patent: June 26, 2018Assignee: BIONEER CORPORATIONInventors: Ji Hee Kang, Byeung I. You, Sung I. Yun, Han O. Park
-
Patent number: RE47123Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.Type: GrantFiled: August 1, 2014Date of Patent: November 13, 2018Assignee: SANOFIInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
-
Patent number: RE47194Abstract: Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: Ab-(L-D)p ??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.Type: GrantFiled: April 7, 2015Date of Patent: January 8, 2019Assignee: Genentech, Inc.Inventors: Jagath R. Junutula, William Mallet
-
Patent number: RE47223Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: June 26, 2015Date of Patent: February 5, 2019Assignee: GENENTECH, INC.Inventors: Mark S. Dennis, Paul Polakis, William Mallet
-
Patent number: RE47300Abstract: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant moiety can be a pro-oxidant vitamin E analogue, such as ?-tocopheryl succinate, ?-tocopheryl maleate, ?-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (?-tocopheryloxyacetic acid).Type: GrantFiled: December 1, 2015Date of Patent: March 19, 2019Assignee: CANCURE LIMITEDInventors: Stephen John Ralph, Jiri Neuzil
-
Patent number: RE47826Abstract: The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.Type: GrantFiled: March 17, 2015Date of Patent: January 28, 2020Assignee: INNOCOLL PHARMACEUTICALS LIMITEDInventors: Michael Myers, Philip Wallace Reginald
-
Patent number: RE48060Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.Type: GrantFiled: June 15, 2016Date of Patent: June 23, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Susan M. Freier
-
Patent number: RE48959Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.Type: GrantFiled: January 4, 2018Date of Patent: March 8, 2022Assignee: SEAGEN INC.Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
-
Patent number: RE49099Abstract: Provided are humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Methods of treatment employing these antibodies are described herein.Type: GrantFiled: May 22, 2019Date of Patent: June 7, 2022Assignee: Bayer Healthcare LLCInventors: Xiao-Yan Zhao, Zhuozhi Wang, Ji-Yun Kim, Ying Zhu, Jan Tebbe
-
Patent number: RE49219Abstract: This invention relates to local administration of a bone-forming agent and at least one anti-resorptive agent to treat osteoporosis and related disorders.Type: GrantFiled: November 21, 2016Date of Patent: September 27, 2022Assignee: DePuy Synthes Products, Inc.Inventors: Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Melissa Grace, Michael Slivka, Thomas G. Ferro, Vivek N. Shenoy, Alonzo D. Cook, Scott Bruder
-
Patent number: RE49435Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: GrantFiled: January 29, 2020Date of Patent: February 28, 2023Assignee: Seagen Inc.Inventors: Julie DeSander, Jeffrey Behrens
-
Patent number: RE49514Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.Type: GrantFiled: September 17, 2020Date of Patent: May 2, 2023Assignees: The Board of Regents of the University of Texas System, Westport Bio, LLCInventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe
-
Patent number: RE49542Abstract: The present invention relates to a method for the diagnosis and/or the follow up of the evolution of cancer, which includes the analysis and quantification of over expressed and amplified genes in the plasma/serum of cancer patients or persons suspected to harbor cancer. This is achieved by analyzing together the amount of DNA and RNA of certain genes in the plasma/serum of cancer patients that are the reflection of a gene amplification and/or a gene over expression in comparison to healthy controls.Type: GrantFiled: September 27, 2013Date of Patent: June 6, 2023Assignee: Guardant Health, Inc.Inventors: Maurice Stroun, Philippe Anker
-
Patent number: RE49774Abstract: The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.Type: GrantFiled: February 11, 2021Date of Patent: January 2, 2024Assignee: MESO SCALE TECHNOLOGIES, LLC.Inventors: Eli N. Glezer, Sudeep Kumar, Pankaj Oberoi, George Sigal, Michael Tsionsky
-
Patent number: RE49816Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R1-R10, X, Y, k, m, n, q, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.Type: GrantFiled: June 4, 2020Date of Patent: January 30, 2024Assignee: CORNELL UNIVERSITYInventors: Gang Lin, Carl Nathan, Aihao Ding, Xiaojing Ma
-
Patent number: RE49835Abstract: A multiplex polymerase chain reaction assay that targets nine tetranucleotide short tandem repeat (STR) markers in the mouse genome. Unique profiles were obtained from seventy-two mouse samples that were used to determine the allele distribution for each STR marker. Correlations between allele fragment length and repeat number were determined with DNA Sanger sequencing. Genotypes for L929 and NIH3T3 cell lines were shown to be stable with increasing passage numbers as there were no significant differences in fragment length with samples of low passage when compared to high passage samples. In order to detect cell line contaminants, primers for two human STR markers were incorporated into the multiplex assay to facilitate detection of human and African green monkey DNA. This multiplex assay is the first of its kind to provide a unique STR profile for each individual mouse sample and can be used to authenticate mouse cell lines.Type: GrantFiled: January 31, 2019Date of Patent: February 13, 2024Assignee: United States of America as Represented by the Secretary of CommerceInventors: Jamie L Almeida, Kenneth D. Cole
-
Patent number: RE49936Abstract: This invention relates generally to the discovery of novel recombinant forms of ?-hexosyl-transferases (BHT) and uses thereof to produce galacto-oligosaccharides (GOS) or as food additives.Type: GrantFiled: December 18, 2020Date of Patent: April 23, 2024Assignee: North Carolina State UniversityInventors: Jose M. Bruno-Barcena, Suzanne Dagher, Maria Azcarate-Peril